Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX01 topical amitriptyline for chemotherapy-induced peripheral neuropathy
2022-000435-23Phase 2Completed
- Sponsor
- AlgoTherapeutix
- Start
- May 2022
- Modality
- Gene Therapies, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ATX-01 in chemotherapy-induced peripheral neuropathy (CIPN) (3 arms), sponsored by AlgoTherapeutix. Primary endpoint: Change in weekly mean average pain intensity at Week 12. Started May 2022; status: completed.
02
Drugs
ATX-01
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on 2022-000435-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000435-23.